Oral Presentation detailsTitle:Novel Oral Rapid-Acting Neuroactive Steroid for Treatment of Postpart

Lipocine (NASDAQ:LPCN) reported quarterly losses of $(0.54) per share which missed the analyst conse

BofA downgrades Carvana (CVNA) to Neutral, cutting the price target to $360. Explore the latest anal

Lipocine stock rebounds after a steep drop as LPCN 1154 misses the Phase 3 endpoint, with encouragin

Wall Street analysts changed their outlook on top names. Check out the ratings page for complete cha

US stocks fall, Dow drops over 50 points, real estate shares rise, Acuity Inc. shares decline, Sky Q

Lipocine Inc. shares are trading lower Thursday after reporting topline safety and efficacy results

US stocks traded lower on Thursday, with the Nasdaq falling 1%. Energy shares rose, while consumer d

In the Phase 3 study population (N=90) of patients with PPD, LPCN 1154 did not show a statistically

HC Wainwright & Co. analyst Yi Chen maintains Lipocine (NASDAQ:LPCN) with a Buy and raises th

Lipocine Inc. (NASDAQ: LPCN), a biopharmaceutical company leveraging its proprietary technology plat

Company on track to report topline results early in the second quarter of 2026Second planned Data an

https://ppubs.uspto.gov/api/pdf/downloadPdf/12502396?requestToken=eyJzdWIiOiJiNGI3ZTk4MS0wOTJiLTQyZj

Second Drug Safety Monitoring Board (DSMB) meeting update planned for mid-January 2026Topline result

Per the Drug Safety Monitoring Board (DSMB) meeting evaluating one-third of planned participants, st

HC Wainwright & Co. analyst Yi Chen maintains Lipocine (NASDAQ:LPCN) with a Buy and lowers th

Lipocine (NASDAQ:LPCN) reported quarterly losses of $(0.59) per share which missed the analyst conse

HC Wainwright & Co. analyst Yi Chen reiterates Lipocine (NASDAQ:LPCN) with a Buy and maintain

Lipocine (NASDAQ:LPCN) reported quarterly losses of $(0.41) per share which missed the analyst conse

HC Wainwright & Co. analyst Yi Chen reiterates Lipocine (NASDAQ:LPCN) with a Buy and maintain

HC Wainwright & Co. analyst Yi Chen reiterates Lipocine (NASDAQ:LPCN) with a Buy and maintain

New Drug Submission filed by Lipocine's licensing partner Verity PharmaOver 700,000 total prescr

New Drug Submission filed by Lipocine's licensing partner Verity PharmaOver 700,000 total prescr

HC Wainwright & Co. analyst Yi Chen assumes Lipocine (NASDAQ:LPCN) with a Buy rating and anno

Lipocine (NASDAQ:LPCN) reported quarterly losses of $(0.35) per share which beat the analyst consens

Lipocine Inc. (NASDAQ:LPCN), a Biopharmaceutical Company Leveraging Its Proprietary Technology Platf

Lipocine Inc. (NASDAQ:LPCN), a biopharmaceutical company leveraging its proprietary technology platf

Lipocine Inc. (NASDAQ:LPCN), a biopharmaceutical company leveraging its proprietary technology platf

Lipocine (NASDAQ:LPCN) reported quarterly losses of $(0.44) per share which beat the analyst consens

Lipocine Inc. (NASDAQ:LPCN), a biopharmaceutical company leveraging its proprietary technology platf

The results indicate robust central nervous system (CNS) activity of oral brexanolone, with concentr

Lipocine Inc. (NASDAQ:LPCN), a biopharmaceutical company leveraging its proprietary technology platf

Alliance Global Partners analyst Scott Henry initiates coverage on Lipocine (NASDAQ:LPCN) with a

Study evaluated LPCN 2401 in participants with obesity (BMI ≥30) and participants with BMI ≥27 with

Lipocine (NASDAQ:LPCN) reported quarterly losses of $(0.56) per share which beat the analyst consens

Met standard bioequivalence (BE) criteria Cmax, AUC0-t, and AUC0-∞Ctrough criterion was metLPCN 1154

 Lipocine Inc. (NASDAQ:LPCN), a biopharmaceutical company, today announced that Phase 2 results on L

Lipocine (NASDAQ:LPCN) reported quarterly earnings of $0.66 per share. This is a 186.84 percent incr

Lipocine Inc. (NASDAQ:LPCN), a biopharmaceutical company, today announced that data from the Phase 2

Lipocine Inc. (NASDAQ:LPCN), a biopharmaceutical company focused on treating Central Nervous System

Positive clinical study results confirm 48-hour dosing regimen for the pivotal PK studyOn track for